secwatch.observer — SEC 8-K summary
======================================

Issuer:     Generation Bio Co. (—)
CIK:        0001733294
Form:       8-K
Filed at:   2026-02-09T23:59:59+00:00
Accession:  0001104659-26-012121
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Generation Bio acquired by XOMA Royalty for $4.29/share + CVR; merger closes, stock delisted
--------------------------------------------------------------------------------

- Merger closed Feb 9, 2026; each share converted to $4.2913 cash plus one non-tradeable CVR.
- 70% of shares tendered; all conditions satisfied; company now wholly owned by XOMA Royalty.
- Cambridge HQ lease terminated Feb 9; ~$21.5M termination fee paid; $2M security deposit returned.
- Former CEO, CFO, and board resigned; Owen Hughes becomes sole director and officer.
- CVR entitles holders to future payments from net cash excess, lease proceeds, legacy assets, or Moderna collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733294/000110465926012121/0001104659-26-012121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733294/000110465926012121/gbio-20260206x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-012121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer